<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508115</url>
  </required_header>
  <id_info>
    <org_study_id>CIR2015/042</org_study_id>
    <nct_id>NCT03508115</nct_id>
  </id_info>
  <brief_title>Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents</brief_title>
  <official_title>Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents. Relationship With Clinical and Sociodemographic Variables</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <brief_summary>
    <textblock>
      Study about the improvement of cognitive, psychopathological and functional abilities in
      Hepatitis C Virus (HCV) infected patients after eradication of the virus with direct
      antiviral agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate the effect that the eradication of the HCV has on
      cognition, quality of life and psychopathology. At the same time, investigators intend to
      study the association between cognitive changes and some clinical variables.

      The sample consists of 80 subjects (40 HCV patients and 40 HCV patients coinfected with the
      Human Immunodeficiency Virus, HIV). Exclusion criteria: Cirrhosis, presence of minimal
      hepatic encephalopathy or active drug consumption.

      A neuropsychological assessment is made before the treatment with direct antiviral agents to
      evaluate memory, executive functions, processing speed, anxiety, depression and quality of
      life. Additionally, the following clinical variables are collected: Viral charge,
      immunosuppression (measured with T Cells CD4 (CD4), CD4 nadir and T Cells CD8 (CD8)) and
      fibrosis level, HCV genotype and plasma biomarkers: Brain-Derived Neurotrophic Factor (BDNF),
      Interleukine 6 (IL6), Tumor Necrosis Factor (TNF-a),Glial fibrillary acidic protein (GFAP),
      Soluble CD14 (SCD14), Neuro-specific enolase (NSE).

      The second neuropsychological assessment and clinical data collection is carried out after
      treatment, concretely 6 months after HCV is undetectable in plasma.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 28, 2016</start_date>
  <completion_date type="Anticipated">December 15, 2018</completion_date>
  <primary_completion_date type="Actual">September 6, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Memory tests</measure>
    <time_frame>baseline, change at 6 months after treatment</time_frame>
    <description>Rey Auditory Verbal Learning Test (RVLT, Spreen &amp; Strauss 1998) assesses verbal learning, recall and recognition memory; Wechsler Adults Intelligence Scale III backward digits subtest (WAIS, Wechsler 1997) assesses working memory. All direct scores have been transformed into T-scores (mean=50; SD=10), which allows to obtain a single memory component.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attention tests</measure>
    <time_frame>baseline, change at 6 months after treatment</time_frame>
    <description>Continous Performance Test (CPT, Conners 2000) assesses sustained attention, inattentiveness and impulsivity; WAIS forward digits subtest (WAIS III, Wechsler 1997) assesses attention. All direct scores have been transformed into T-scores (mean=50; SD=10), which allows to obtain a single attention component.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Executive function tests</measure>
    <time_frame>baseline, change at 6 months after treatment</time_frame>
    <description>Stroop Test (Stroop, 1935) assesses flexibility and inhibition of automatic responses; Trail Making Test (TMTA-B Reitan, 1993) assesses visual tracking and flexibility, phonetic and semantic fluency tests (Lezak, 1995) assess verbal fluency; Tower of London (Culbertson &amp; Zillmer, 2005) assesses visual reasoning and planification. All direct scores have been transformed into T-scores (mean=50; SD=10), which allows to obtain a single executive function component.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Speed processing test</measure>
    <time_frame>baseline, change at 6 months after treatment</time_frame>
    <description>Digit symbol test (WAIS III, Wechsler 1997) assesses visuomotor speed. The direct scores have been transformed into T-scores (mean=50; SD=10).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>baseline, change at 6 months after treatment</time_frame>
    <description>It is a self-registering scale of 14 items: 7 items evaluating anxiety and 7 items evaluating depression (Zigmond &amp; Snaith, 1983).
Scoring range: 0-21 for each subscale. Scores &gt;10 in each subscale imply a significant anxious/depressive symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Health Survey (SF-36 )</measure>
    <time_frame>baseline, change at 6 months after treatment</time_frame>
    <description>It is a self-registered scale for the assessment of quality of life ( Alonso y cols. , 1995). It consists on 8 dimensions: Physical functioning, limitations for physical issues, corporal pain, social functioning, mental health, limitations for emotional issues, vitality and general perception of the own health. For each dimension, the scoring range goes from 0 to 100, where higher values represent better outcome (better quality of life/less limitations/better functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan</measure>
    <time_frame>Baseline, change at 6 months after treatment</time_frame>
    <description>Degree of fibrosis: Speed of propagation of elastic waves measured with fibroscan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA</measure>
    <time_frame>Baseline, change at 3 months after treatment, change at 6 months after treatment.</time_frame>
    <description>Viral load quantity measured by plasma HCV RNA is collected in HIV co-infected patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunosuppression state</measure>
    <time_frame>Baseline</time_frame>
    <description>The next cells were analyzed in blood, in HIV co-infected patients : CD4, %CD4, nadir CD4, CD8, % CD8, CD4/CD8 ratio.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood Biomarkers measures</measure>
    <time_frame>1 day pretreatment and change at 6 months post treatment</time_frame>
    <description>The next blood biomarkers were collected: Brain-derived neurotrophic factor (BDNF); Interleukine 6 (Il-6); Tumor Necrosis Factor (TNF-a ); Glial fibrillary acidic protein (GFAP); Soluble SCD 14 (sCD14) ; Neuro-specific enolase (NSE).</description>
  </other_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HCV Infection</condition>
  <condition>HCV Coinfection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HCV patients who are candidates to direct antiviral treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old with indication to receive antiviral treatment

          -  Diagnosis of chronic infection by hepatitis C virus in the fibrous phase F3 or F4 that
             have not presented any clinical decompensation of their liver disease, with or without
             HIV co-infection

        Exclusion Criteria:

          -  Active alcohol consumption&gt; 40g daily or history of chronic alcoholism

          -  Active consumption of other toxics (heroin, cocaine, cannabis)

          -  Patients with minimum hepatic encephalopathy

          -  Background of cerebral neurological disease, chronic renal insufficiency and / or
             psychiatric illnesses assessed according to the Diagnostic and Statistical Manual of
             Mental Disorders (DSM-5) criteria, which can affect cognitive functions.

          -  Active use of psychotropics or benzodiazepines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Merc√® Jodar-Vicente</investigator_full_name>
    <investigator_title>Clinical Neuropsychologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

